ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
ROME Therapeutics has raised $72.0M in total funding. The most recent round was Series B. The last funding was announced in September 2023.
ROME Therapeutics's investors include Andreessen Horowitz, S32, ARCH Venture Partners, Bristol-Myers Squibb, Alexandria Venture Investments.
ROME Therapeutics is headquartered in Cambridge, United States.
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
ROME Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ROME Therapeutics — Funding & Investors." VCBacked, September 12, 2023, https://www.vcbacked.co/company/rome-therapeutics. Accessed July 19, 2026.
VCBacked. (2023). ROME Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/rome-therapeutics
{{cite web |title=ROME Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/rome-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated